This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Silverman, J. A.
Right arrow Articles by Joiner, K. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Silverman, J. A.
Right arrow Articles by Joiner, K. A.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, Sep 1997, 1859-1866, Vol 41, No. 9
Copyright © 1997 by the American Society for Microbiology. All rights reserved.

Characterization of anti-Toxoplasma activity of SDZ 215-918, a cyclosporin derivative lacking immunosuppressive and peptidyl-prolyl- isomerase-inhibiting activity: possible role of a P glycoprotein in Toxoplasma physiology

JA Silverman, ML Hayes, BJ Luft and KA Joiner
Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut 06520-8022, USA.

The immunosuppressive agent cyclosporin A (CsA) also possesses broad- spectrum antimicrobial activity. Previous investigators have reported that the obligate intracellular protozoan Toxoplasma gondii is sensitive to CsA. We have measured the sensitivity of Toxoplasma to 26 CsA derivatives that maintain only a subset of the parent compound's activity. We identified one compound, SDZ 215-918, that is a particularly potent inhibitor of parasite invasion and replication, with a 50% inhibitory concentration of 0.45 microg/ml, which is 10-fold lower than that of CsA. Kinetic studies demonstrate that activity has a rapid onset (half-life, < or = 20 min) and is initially reversible, although long-term exposure (> 24 h) to 5 microg/ml is lethal; in contrast, this concentration had no effect on host cell protein synthesis or cell division. SDZ 215-918 acts directly on the parasite, as demonstrated by inhibition of macromolecular synthesis in host-free extracellular parasites. Inhibition of invasion is due to a reduction in parasite motility. SDZ 215-918 does not bind to cyclophilins, the ubiquitous cyclosporin-binding proteins, but is a potent inhibitor of the mammalian P glycoprotein, a member of the ATP binding cassette transporter superfamily and the pump responsible for multidrug resistance in cancer and parasite cell lines. SDZ 215-918 blocks the efflux of rhodamine 123 from extracellular parasites, consistent with inhibition of a P glycoprotein-like pump. We suggest that a P glycoprotein or a related transporter plays a crucial role in the biology of Toxoplasma and may be a novel target for antiparasitic compounds. Preliminary studies with animals indicate that SDZ 215-918 inhibits parasite growth in vivo; its relationship to CsA may make it suitable for clinical development.


This article has been cited by other articles:

  • Bottova, I., Hehl, A. B., Stefanic, S., Fabrias, G., Casas, J., Schraner, E., Pieters, J., Sonda, S. (2009). Host Cell P-glycoprotein Is Essential for Cholesterol Uptake and Replication of Toxoplasma gondii. J. Biol. Chem. 284: 17438-17448 [Abstract] [Full Text]  
  • D'Angelo, J. G., Bordon, C., Posner, G. H., Yolken, R., Jones-Brando, L. (2009). Artemisinin derivatives inhibit Toxoplasma gondii in vitro at multiple steps in the lytic cycle. J Antimicrob Chemother 63: 146-150 [Abstract] [Full Text]  
  • Sonda, S., Sala, G., Ghidoni, R., Hemphill, A., Pieters, J. (2005). Inhibitory Effect of Aureobasidin A on Toxoplasma gondii. Antimicrob. Agents Chemother. 49: 1794-1801 [Abstract] [Full Text]  
  • Marchetti, O., Moreillon, P., Entenza, J. M., Vouillamoz, J., Glauser, M. P., Bille, J., Sanglard, D. (2003). Fungicidal Synergism of Fluconazole and Cyclosporine in Candida albicans Is Not Dependent on Multidrug Efflux Transporters Encoded by the CDR1, CDR2, CaMDR1, and FLU1 Genes. Antimicrob. Agents Chemother. 47: 1565-1570 [Abstract] [Full Text]  
  • Leitch, G. J., Scanlon, M., Shaw, A., Visvesvara, G. S. (2001). Role of P Glycoprotein in the Course and Treatment of Encephalitozoon Microsporidiosis. Antimicrob. Agents Chemother. 45: 73-78 [Abstract] [Full Text]  
  • Marchetti, O., Entenza, J. M., Sanglard, D., Bille, J., Glauser, M. P., Moreillon, P. (2000). Fluconazole plus Cyclosporine: a Fungicidal Combination Effective against Experimental Endocarditis Due to Candida albicans. Antimicrob. Agents Chemother. 44: 2932-2938 [Abstract] [Full Text]  
  • Marchetti, O., Moreillon, P., Glauser, M. P., Bille, J., Sanglard, D. (2000). Potent Synergism of the Combination of Fluconazole and Cyclosporine in Candida albicans. Antimicrob. Agents Chemother. 44: 2373-2381 [Abstract] [Full Text]  
  • Coppens, I., Sinai, A. P., Joiner, K. A. (2000). Toxoplasma gondii Exploits Host Low-Density Lipoprotein Receptor-Mediated Endocytosis for Cholesterol Acquisition. JCB 149: 167-180 [Abstract] [Full Text]  
  • Cardenas, M. E., Cruz, M. C., Del Poeta, M., Chung, N., Perfect, J. R., Heitman, J. (1999). Antifungal Activities of Antineoplastic Agents: Saccharomyces cerevisiae as a Model System To Study Drug Action. Clin. Microbiol. Rev. 12: 583-611 [Abstract] [Full Text]  
  • Perkins, M. E., Riojas, Y. A., Wu, T. W., Le Blancq, S. M. (1999). CpABC, a Cryptosporidium parvum ATP-binding cassette protein at the host-parasite boundary in intracellular stages. Proc. Natl. Acad. Sci. USA 96: 5734-5739 [Abstract] [Full Text]  
  • Perkins, M. E., Wu, T. W., Le Blancq, S. M. (1998). Cyclosporin Analogs Inhibit In Vitro Growth of Cryptosporidium parvum. Antimicrob. Agents Chemother. 42: 843-848 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»